Genomic urine testing market seen topping $2 billion by 2030

By AI, Created 4:59 PM UTC, May 18, 2026, /AGP/ – The Business Research Company projects the genomic urine testing market will pass $2 billion by 2030, led by North America and the U.S. The report points to rising demand for non-invasive diagnostics, precision medicine and early disease detection as the main growth drivers.

Why it matters: - Genomic urine testing is moving from a niche diagnostic tool toward a broader clinical market. - The report estimates the category will surpass $2 billion by 2030, equal to about 1% of the medical laboratory services market. - The market is also projected to represent nearly 0.02% of the broader healthcare services industry. - Growth matters because urine-based genomics can reduce the need for biopsies and blood draws while supporting earlier detection and monitoring.

What happened: - The Business Research Company released a market report on genomic urine testing dated May 12, 2026. - The report says North America will be the largest region in 2030, with a market value of $1.00 billion. - The U.S. will be the largest country in 2030, valued at $0.92 billion. - The report places the overall market CAGR at 12% leading up to 2030. - A free sample is available here. - The full report is available here.

The details: - North America is expected to grow from $0.62 billion in 2025 to $1.00 billion in 2030, a 10% CAGR. - The U.S. market is expected to grow from $0.59 billion in 2025 to $0.92 billion in 2030, a 9% CAGR. - DNA testing is the largest testing-type segment and is projected to account for 43% of the market, or about $1 billion, in 2030. - The market also includes RNA testing, microbial testing and epigenetic testing. - By distribution channel, the market is split across hospital pharmacies, mail order pharmacies and speciality pharmacies. - By application, the report segments the market into cancer diagnosis, infectious diseases, genetic disorder screening and health monitoring. - By end user, the market covers hospitals and clinics, diagnostic laboratories, research and academic institutions and other users. - DNA testing is supported by high sensitivity for genetic mutations and disease-specific biomarkers, growing oncology use, hereditary disease identification, next-generation sequencing and preference for reproducible genomic diagnostics. - The report says the biggest growth drivers are non-invasive diagnostics, precision medicine and rising cancer and chronic disease burden. - Non-invasive diagnostics are expected to add about 2.8% annual growth to the market. - Precision medicine is projected to contribute around 2.5% annual growth. - Cancer and chronic disease burden is projected to contribute about 2.3% annual growth.

Between the lines: - The market forecast points to a diagnostic shift toward tests that are easier to repeat and integrate into routine care. - The strongest revenue concentration remains in North America, especially the U.S., which suggests adoption is being led by advanced healthcare infrastructure and research activity. - DNA testing appears to be the commercial anchor, while RNA, microbial and epigenetic testing look like the next layers of expansion. - The report’s growth logic centers on the same three pressures across healthcare: lower invasiveness, more personalized treatment and earlier detection.

What’s next: - The report expects the largest opportunities over the next five years to come from DNA, RNA, microbial and epigenetic testing. - Those segments are projected to add more than $0.7 billion in combined value by 2030. - DNA testing is projected to grow by $0.3 billion from 2025 to 2030. - RNA testing is projected to grow by $0.2 billion. - Microbial testing is projected to grow by $0.1 billion. - Epigenetic testing is projected to grow by $0.1 billion. - Continued advances in sequencing, biomarker identification and multi-omics diagnostics are expected to support adoption. - The Business Research Company says it has published more than 17,500 reports across 27 industries and 60+ geographies, backed by 1,500,000 datasets and interviews with industry leaders.